Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells

Cancer Research

Volumn 73, Issue 4, 2013, Pages 1411-1419

  Kho, Dhong Hyo ^a,b   Nangia Makker, Pratima ^a   Balan, Vitaly ^a,b   Hogan, Victor ^a,b   Tait, Larry ^a,b   Wang, Yi ^a,b   Raz, Avraham ^a,b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCOSE 6 PHOSPHATE ISOMERASE; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; GLUCOSE-6-PHOSPHATE ISOMERASE; HEK293 CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR, ERBB-2; RECEPTORS, AUTOCRINE MOTILITY FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84874287249     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2149     Document Type: Article

References (40)

1. Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 2007;26:6577-92. (Pubitemid 47573679)
2. Hynes NE, Lane HA. (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-4.
3. Moasser M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007;26:6469-87. (Pubitemid 47530601)
4. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, DenneyDWJr., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60. (Pubitemid 36227628)
5. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003;12:541-52. (Pubitemid 37222478)
6. Kita Y, Tseng J, Horan T, Wen J, Philo J, Chang D, et al. ErbB receptor activation, cell morphology changes, and apoptosis induced by anti- Her2 monoclonal antibodies. Biochem Biophys Res Commun 1996; 226:59-69. (Pubitemid 26332164)
7. Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci U S A 1991;88:8691-5.
8. Pohlmann PR, Mayer IA, Mernaugh A. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009;15:7479-91.
9. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
10. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L, et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011;29:16-32
11. Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005;65:473-82.
12. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6:117-27. (Pubitemid 39485684)
13. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007;99:628-38. (Pubitemid 47073544)
14. Saez R, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006;12:424-31. (Pubitemid 43166131)
15. Fairbank M, St-Pierre P, Nabi IR. The complex biology of autocrine motility factor/phosphoglucose isomerase (AMF/PGI) and its receptor, the gp78/AMFR E3 ubiquitin ligase. Mol Biosyst 2009;5: 793-801.
16. Jeffery CJ. Moonlighting proteins - an update. Mol Biosyst 2009; 5:345-50.
17. Chaput M, Claes V, Portetelle D, Cludts I, Cravador A, Burny A, et al. The neurotrophic factor neuroleukin is 90% homologous with phosphohexose isomerase. Nature 1988;332:454-5.
18. Liotta LA, Mandler R, Murano G, Katz DA, Gordon RK, Chiang PK, et al. Tumor cell autocrine motility factor. Proc Natl Acad Sci U S A 1986;83:3302-6.
19. Baumann M, Kappl A, Lang T, Brand K, Siegfried W, Paterok E. The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney, and breast cancer. Cancer Invest 1990;8:351-6.
20. Tsutsumi S, Hogan V, Nabi NR, Raz A. Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts. Cancer Res 2003;63: 242-9.
21. Araki K, Shimura T, Yajima T, Tsutsumi S, Suzuki H, Okada K, et al. Phosphoglucose isomerase/autocrine motility factor promotes melanoma cell migration through ERK activation dependent on autocrine production of interleukin-8. J Biol Chem 2009;284:32305-11.
22. Shimizu K, Tani M, Watanabe H, Nagamachi Y, Niinaka Y, Shiroishi T, et al. The autocrine motility factor receptor gene encodes a novel type of seven transmembrane protein. FEBS Lett 1999;456:295-300. (Pubitemid 29352311)
23. Haga A, Komazaki S, Funasaka T, Hashimoto K, Yokoyama Y, Watanabe H, et al. AMF/G6PI induces differentiation of leukemic cells via an unknown receptor that differs from gp78. Leuk Lymphoma 2006;47: 2234-43. (Pubitemid 44650103)
24. EvansCP, Walsh DS, Kohn EC. An autocrine motility factor secreted by the Dunning R-3327 rat prostatic adenocarcinoma cell subtype AT2.1. Int J Cancer 1991;49:109-13.
25. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011;10:47-60.
26. Arribas J, Baselga J, Pedersen K, Parra-Palau JL. p95HER2 and breast cancer. Cancer Res 2011;71:1515-19.
27. Read J, Pearce J, Li X, Muirhead H, Chirgwin J, Davies C. The crystal structure of human phosphoglucose isomerase at 1.6 A resolution: implications for catalytic mechanism, cytokine activity and haemolytic anaemia. J Mol Biol 2001;309:447-63. (Pubitemid 32564905)
28. Shekhar MP, Nangia-Makker P, Tait L, Miller F, Raz A. Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol 2004;165:1931-41. (Pubitemid 39578372)
29. Fang S, Ferrone M, Yang C, Jensen JP, Tiwari S, Weissman AM. The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. Proc Natl Acad Sci U S A 2001;98:14422-7 (Pubitemid 33121407)
30. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007;7:389-97. (Pubitemid 46652484)
31. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89:10578-82.
32. Siegel PM, Dankort DL, Hardy WR, Muller WJ. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 1994;14:7068-77. (Pubitemid 24326370)
33. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12. (Pubitemid 19147683)
34. Kwong KY, Hung MC. A novel splice variant of HER2 with increased transformation activity. Mol Carcinog 1998;23:62-8.
35. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms ofNeu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999;18:2149-64. (Pubitemid 29179172)
36. Arribas J, Parra-Palau JL, Pedersen K. HER2 fragmentation and breast cancer stratification. Clin Cancer Res 2010;16:4071-3.
37. Pedersen K, Angelini PD, Laos S, Bach-Faig A, Cunningham MP, Ferrer-Ram-on C, et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol 2009;29:3319-31.
38. Tse C, Gauchez AS, Jacot W, Lamy PJ. HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer. Cancer Treat Rev 2011;38:133-42.
39. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61:4744-9.
40. Talukder AH, Bagheri-Yarmand R, Williams RR, Ragoussis J, Kumar R, Raz A. Antihuman epidermal growth factor receptor 2 antibody Herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors. Clin Cancer Res 2002;8: 3285-9.